MedinCell provides an update on its product portfolio, following the FDA Acceptance of New Drug Application for the product mdc-IRM

September 1, 2021

Conference held today for shareholders and the financial community:
▪ Conference in French at 6:00 pm (CEST)
▪ Conference in English at 7:00 pm (CEST)
▪ Connection link:

MedinCell and Teva announced yesterday the FDA acceptance of the New Drug Application for mdc-IRM for patients with schizophrenia

This first long-acting injectable treatment based on MedinCell’s technology could be commercialized as early as 2022 by Teva in the U.S.

Upcoming portfolio milestones expected:

▪ mdc-TJK and mdc-ANG: Announcement of next steps by Teva expected by year-end.

▪ mdc-CWM: Our partner AIC is targeting FDA approval to initiate Phase 3 efficacy studies before the end of 2021. The start of the safety study has been postponed.

▪ mdc-TTG: MedinCell is awaiting the approval of health authorities in several European countries, including France, to initiate a multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial to confirm the prophylactic efficacy of ivermectin in regular, daily, oral form to simulate the continuous release of the active ingredient by a long-acting injectable.

Session en français

Rendez-vous le lundi 14 novembre à 18h00 (CET) pour une vidéoconférence dédiée aux récentes avancées des produits de notre portfeuille clinique

English session

On Monday 14, November at 6.00 pm (CET) participate in our videoconference dedicated to the latest news regarding our clinical and regulatory products

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.